Cargando…

Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan

BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuppini, Lucia, Calleri, Angelica, Bruzzone, Maria Grazia, Prodi, Elena, Anghileri, Elena, Pellegatta, Serena, Mancuso, Patrizia, Porrati, Paola, Di Stefano, Anna Luisa, Ceroni, Mauro, Bertolini, Francesco, Finocchiaro, Gaetano, Eoli, Marica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772091/
https://www.ncbi.nlm.nih.gov/pubmed/24069296
http://dx.doi.org/10.1371/journal.pone.0074345
_version_ 1782284282022068224
author Cuppini, Lucia
Calleri, Angelica
Bruzzone, Maria Grazia
Prodi, Elena
Anghileri, Elena
Pellegatta, Serena
Mancuso, Patrizia
Porrati, Paola
Di Stefano, Anna Luisa
Ceroni, Mauro
Bertolini, Francesco
Finocchiaro, Gaetano
Eoli, Marica
author_facet Cuppini, Lucia
Calleri, Angelica
Bruzzone, Maria Grazia
Prodi, Elena
Anghileri, Elena
Pellegatta, Serena
Mancuso, Patrizia
Porrati, Paola
Di Stefano, Anna Luisa
Ceroni, Mauro
Bertolini, Francesco
Finocchiaro, Gaetano
Eoli, Marica
author_sort Cuppini, Lucia
collection PubMed
description BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated in 68 patients affected by recurrent glioblastoma (rGBM) treated with bevacizumab and irinotecan and two Independent Datasets of rGBM patients respectively treated with bevacizumab alone (n=32, independent dataset A: IDA) and classical antiblastic chemotherapy (n=14, independent dataset B: IDB). METHODS: rGBM patients with KPS ≥50 were treated until progression, as defined by MRI with RANO criteria. CECs expressing CD109, a marker of tumor endothelial cells, as well as other CEC and CEP subtypes, were investigated by six-color flow cytometry. RESULTS: A baseline count of CD109+ CEC higher than 41.1/ml (1(st) quartile) was associated with increased progression free survival (PFS; 20 versus 9 weeks, P=0.008) and overall survival (OS; 32 versus 23 weeks, P=0.03). Longer PFS (25 versus 8 weeks, P=0.02) and OS (27 versus 17 weeks, P=0.03) were also confirmed in IDA with CD109+ CECs higher than 41.1/ml but not in IDB. Patients treated with bevacizumab with or without irinotecan that were free from MRI progression after two months of treatment had significant decrease of CD109+ CECs: median PFS was 19 weeks; median OS 29 weeks. The presence of two non-contiguous lesions (distant disease) at baseline was an independent predictor of shorter PFS and OS (P<0.001). CONCLUSIONS: Data encourage further studies on the predictive potential of CD109+ CECs in GBM patients treated with bevacizumab.
format Online
Article
Text
id pubmed-3772091
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37720912013-09-25 Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan Cuppini, Lucia Calleri, Angelica Bruzzone, Maria Grazia Prodi, Elena Anghileri, Elena Pellegatta, Serena Mancuso, Patrizia Porrati, Paola Di Stefano, Anna Luisa Ceroni, Mauro Bertolini, Francesco Finocchiaro, Gaetano Eoli, Marica PLoS One Research Article BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated in 68 patients affected by recurrent glioblastoma (rGBM) treated with bevacizumab and irinotecan and two Independent Datasets of rGBM patients respectively treated with bevacizumab alone (n=32, independent dataset A: IDA) and classical antiblastic chemotherapy (n=14, independent dataset B: IDB). METHODS: rGBM patients with KPS ≥50 were treated until progression, as defined by MRI with RANO criteria. CECs expressing CD109, a marker of tumor endothelial cells, as well as other CEC and CEP subtypes, were investigated by six-color flow cytometry. RESULTS: A baseline count of CD109+ CEC higher than 41.1/ml (1(st) quartile) was associated with increased progression free survival (PFS; 20 versus 9 weeks, P=0.008) and overall survival (OS; 32 versus 23 weeks, P=0.03). Longer PFS (25 versus 8 weeks, P=0.02) and OS (27 versus 17 weeks, P=0.03) were also confirmed in IDA with CD109+ CECs higher than 41.1/ml but not in IDB. Patients treated with bevacizumab with or without irinotecan that were free from MRI progression after two months of treatment had significant decrease of CD109+ CECs: median PFS was 19 weeks; median OS 29 weeks. The presence of two non-contiguous lesions (distant disease) at baseline was an independent predictor of shorter PFS and OS (P<0.001). CONCLUSIONS: Data encourage further studies on the predictive potential of CD109+ CECs in GBM patients treated with bevacizumab. Public Library of Science 2013-09-12 /pmc/articles/PMC3772091/ /pubmed/24069296 http://dx.doi.org/10.1371/journal.pone.0074345 Text en © 2013 Cuppini et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Cuppini, Lucia
Calleri, Angelica
Bruzzone, Maria Grazia
Prodi, Elena
Anghileri, Elena
Pellegatta, Serena
Mancuso, Patrizia
Porrati, Paola
Di Stefano, Anna Luisa
Ceroni, Mauro
Bertolini, Francesco
Finocchiaro, Gaetano
Eoli, Marica
Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
title Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
title_full Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
title_fullStr Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
title_full_unstemmed Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
title_short Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
title_sort prognostic value of cd109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772091/
https://www.ncbi.nlm.nih.gov/pubmed/24069296
http://dx.doi.org/10.1371/journal.pone.0074345
work_keys_str_mv AT cuppinilucia prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT calleriangelica prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT bruzzonemariagrazia prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT prodielena prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT anghilerielena prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT pellegattaserena prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT mancusopatrizia prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT porratipaola prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT distefanoannaluisa prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT ceronimauro prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT bertolinifrancesco prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT finocchiarogaetano prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan
AT eolimarica prognosticvalueofcd109circulatingendothelialcellsinrecurrentglioblastomastreatedwithbevacizumabandirinotecan